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Abstract
Accumulating evidence indicates that G protein-coupled receptor kinase 2 (GRK2) is a versatile protein that acts as a signal-
ing hub by modulating G protein-coupled receptor (GPCR) signaling and also via phosphorylation or scaffolding interactions 
with an extensive number of non-GPCR cellular partners. GRK2 multifunctionality arises from its multidomain structure 
and from complex mechanisms of regulation of its expression levels, activity, and localization within the cell, what allows 
the precise spatio-temporal shaping of GRK2 targets. A better understanding of the GRK2 interactome and its modulation 
mechanisms is helping to identify the GRK2-interacting proteins and its substrates involved in the participation of this kinase 
in different cellular processes and pathophysiological contexts.
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Introduction
G protein-coupled receptor kinases (GRKs) constitute a fam-
ily of seven serine/threonine protein kinases that specifically 
phosphorylate agonist-activated G protein-coupled recep-
tors (GPCRs). Receptor phosphorylation triggers the bind-
ing of cytoplasmic β-arrestin molecules, which sterically 
block interaction with heterotrimeric G proteins, leading to 
rapid desensitization of G protein-mediated signaling cas-
cades. Moreover, β-arrestins-bound GPCRs are targeted for 
clathrin-mediated endocytosis, a process that serves to de-
phosphorylate, re-sensitize, and eventually recycle receptors 
back to the plasma membrane [1–5]. Beyond this canonical 
role in GPCRs desensitization, GRKs are instrumental in 
triggering G protein-independent GPCR signaling through 
β-arrestins, since the latter are scaffold proteins for many 
cellular partners, able to assemble complex GPCR signa-
losomes. Both the ligand-induced conformational changes 
and the phosphorylation pattern (called phosphorylation bar-
coding) imprinted by GRKs on GPCRs could be important 
for determining the balance between G protein activation, 
GPCRs desensitization, and GRK/β-arrestin-mediated sign-
aling [6–10].
On the other hand, it is worth noting that the impact of 
changes in GRK expression and functionality in cells might 
also involve non-GPCR targets. Thus, GRKs and, in par-
ticular, the ubiquitous and essential GRK2 isoform, are 
emerging as signal transducers by themselves, being able to 
interact with (and in many cases, phosphorylate) a variety of 
non-GPCR proteins [2, 5, 11–14] see also below). Consistent 
with such complex interactomes, GRK2 has been reported 
to participate in many cellular and physiological processes 
(cardiac contractility, cell proliferation, cell cycle regulation, 
angiogenesis, vasodilatation, cell migration, inflammation 
and metabolic homeostasis, to name some relevant exam-
ples). The changes in GRK2 levels and functionality taking 
place in different pathological contexts were suggested to 
play a key role in disease progression [11, 15–20].
Therefore, a main current challenge is to elucidate the 
GPCR and/or non-GPCR GRK2 cellular partners that are 
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involved in the physiological and pathological roles of this 
kinase and to better understand how GRK2 interaction net-
works are engaged in a stimulus-, cell type-, or context-
specific manner. Such GRK2 multifunctionality appears to 
arise from its multidomain structure and also from complex 
mechanisms of regulation that determine GRK2 expression 
levels, activity, localization within the cell, and partner/tar-
get selection.
An overview of the complexity of the GRK2 
interactome
In addition to its canonical role in agonist-stimulated GPCR 
phosphorylation, GRK2 has been reported to establish 
functional or scaffolding interactions with an extensive and 
increasing number of cellular partners (reviewed in [2, 11, 
12, 21]. Alternative GRK2 substrates and/or interactors 
include non-GPCR membrane receptors and proteins (such 
as PDGF or EGF receptor tyrosine kinases or the ENaC 
sodium channel), key cellular kinases (p38Mapk, AMPK, 
PI3K/AKT, MEK1, MST1), signal transducers and switchers 
(IRS1, RKIP, EPAC1, Pin1, Patched, PDEγ, eNOS, APC, 
Gαq, Gβγ, phosducin; RhoA, RalA), transcription factors 
and modulators (Smad2/3, Period1/2, IκBα, DREAM), E3 
ubiquitin ligases and chaperones (Mdm2, Cul4A-DDB1-Gβ, 
Nedd4-2, Hsp90), ribosomal proteins, membrane compo-
nents (clathrin, caveolin), mitochondrial proteins (Mito-
fusin1/2) or cytoskeleton components, and regulators 
(HDAC6, ezrin/radixin, tubulin, GIT1, α-actinin) (see 
Table 1 for the references and description of these GRK2 
partners).
Since the role of GRK2 in different cellular processes 
and physiological functions is the result of the integration of 
its canonical and non-canonical interactomes, it is a key to 
validate these interactions and clearly determine their func-
tional impact in relevant experimental models and to better 
understand the stimuli and mechanisms linking GRK2 to its 
potential partners in specific contexts.
GRK2 structure: a versatile multidomain 
protein
GRKs are multidomain molecules that emerged at early 
stages of eukaryotic evolution [22] and that display either 
ubiquitous (GRK2, 3, 5, and 6), more restricted (GRK4) 
or cell-type specific (GRK1 and 7) expression patterns [11, 
14]. The N-terminal region (αN-helix), characteristic of this 
protein family and important for receptor recognition, is fol-
lowed by a domain displaying homology to RGS proteins 
(thus termed RGS homology, or RH domain), reported to 
associate with G protein alpha subunits. In the case of GRK2 
and GRK3, the RH domain has been shown to interact with 
GTP-liganded Gαq family members [23, 24]. A central 
catalytic domain with high similarity to other AGC pro-
tein kinases, such as PKA, PKB, and PKC, is shared by all 
GRKs, whereas a more variable carboxyl-terminal domain 
is important for the localization and translocation of GRKs 
to the membrane by means of either post-translational modi-
fications or sites of interaction with lipids or membrane-
bound proteins [12, 25] (Fig. 1). Membrane targeting can 
be achieved via prenylation (in GRK1 and 7), palmitoylation 
(in GRK4 and 6), a positively charged lipid-binding element 
(in GRK5) or binding to membrane phospholipids and Gβγ 
subunits via a pleckstrin homology (PH) domain (in GRK2 
and 3).
To date, all mammalian GRKs (except GRK3 and GRK7) 
have been crystallized (see [26] and references therein). 
The GRK2 structure in complex with Gβγ subunits [27], 
followed by the crystallization of GRK2 alone [28] and in 
complex with Gβγ and Gαq subunits [29], provided exciting 
insights into GRK regulation. The structural data placed the 
three defined GRK2 domains (RH, kinase, and PH regions) 
at the vertices of a triangle and constituted an excellent 
example of how multiple modular domains can integrate 
in a single molecule to transduce and modulate signaling 
events. Such structural design would allow the coordinated 
control of GRK2 activity and membrane targeting upon 
GPCR stimulation via dynamic interactions of the different 
GRK2 domains among themselves and with different intra-
cellular targets [12, 25, 26].
The bilobular fold of the catalytic domain of GRK2 is 
very similar to that of other AGC kinases and highly con-
served among GRKs subfamilies. It consists of an N-termi-
nal small kinase lobe (aa 186–272 and aa 496–513) and a 
C-terminal large lobe (aa 273–475), sandwiching the cata-
lytic cleft, which is stabilized by the interposition of the αC 
helix coming from the small lobe. As part of the nucleotide 
gate, a C-terminal extension to the large lobe, the active 
site tether (AST, aa 475–485), passes over the cleft con-
tributing to stabilize the nucleotide and phosphor-acceptor 
binding sites in the active kinase. In many AGC kinases, 
transitions from inactive conformations (characterized by 
expanded lobes and disordered nucleotide gate and αC helix) 
to the active conformation involve phosphorylation of sev-
eral regulatory motifs at the activation segment/loop, which 
is located in the large kinase lobe, and at the hydrophobic 
motif, which is found C-terminal to the small kinase lobe 
and is sometimes preceded by another important structural 
determinant, the turn motif. Phosphorylation of these sites 
coordinates the closure of catalytic lobes and stabilizes the 
active conformation of the αC helix [30]. In contrast, GRK2 
lacks phospho-acceptor sites in the equivalent regulatory 
motifs, and the RH domain serves as an intra-molecular 
scaffold that maintains the small lobe of the kinase domain 
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and the αC helix in a competent configuration and helps 
to maintain the kinase domain in an inactive, open confor-
mation [31–33]. Therefore, activation of GRK2 appears to 
rely on interaction of its different domains with activating 
interactors (agonist-occupied GPCR, Gβγ subunits). This 
allows readjustment of the kinase domain contacts with the 
N-terminal helix and the RH and PH domains, ultimately 
leading to allosteric rearrangement of the AST and kinase 































































































































































































































































































ls Fig. 1  Multi-domain structural organization of GRK2. The three 
modular domains of GRK2 are sketched out: the N-terminal RGS 
(regulator of G protein signaling) homology (RH) domain (in blue), 
the bilobular central kinase domain (gray), and the C-terminal pleck-
strin homology (PH) domain (green). The RH domain contacts both 
the kinase and PH domains and the RH domain–PH domain inter-
face allows a possible route for allosteric communication. Binding of 
diverse molecules (proteins, phospholipids) to PH and RH domains 
and post-translational modifications of these domains (Y86, Y92, 
S670, S685, phosphorylation sites denoted in red) may affect the 
interface between RH and kinase lobes, and thus GRK2 catalytic 
activity. Residues indicated in the terminal αN-helix of GRK2 are 
packed against the AST loop (M17, L14, Y13, D10) and are critical 
for phosphorylation of GPCRs and cytosolic substrates, highlighting 
their role in the spatial arrangement of AST and of the kinase domain 
extension known as C-tail, which is required for kinase domain clo-
sure and activity. Other residues of the αN-helix are positioned away 
from the catalytic hinge and participate in GPCR recruitment, form-
ing a hydrophobic patch for docking (L4, V7, L8, V11, S12) and also 
conveying allosteric activation to the kinase domain (D3, L4). Some 
of these exposed residues (D3) are involved in differential interac-
tions with GPCR allowing binding selectivity. Phosphorylation of key 
αN-helix residues (Y13) or nearby residues (S29) may impact GRK2 
catalytic activity and GPCR docking. See main text for details
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Several studies support the notion that multiple GPCR and 
GRK regions are involved in their interaction [26, 34–36]. The 
αN-helix appears to stabilize the kinase domain closure via a 
process that may be regulated by GPCR binding [37–39], and 
truncation or point mutations of the N terminus of GRKs leads 
to nearly complete loss of receptor phosphorylation [40–43]. 
However, it is still not clear to which extent this region is 
directly involved in receptor binding or in facilitating kinase 
activity and receptor phosphorylation [26].
Besides the αΝ-helix domain, a proline-rich motif located 
just before the nucleotide gate has been identified in GRK2 
as relevant for receptor binding [44, 45], and several studies 
suggest an important role for the RH domain of GRKs in 
receptor interaction [46–50].
In this regard, the recent structure of GRK5 with the 
β2AR [51] suggests that GRKs display high structural plas-
ticity, showing a dynamic mechanism of complex forma-
tion that involves large conformational changes in the GRK5 
RH/catalytic domain interface upon receptor binding. These 
changes facilitate contacts between intracellular loops 2 and 
3 and the C terminus of the β2AR with the GRK5 RH bundle 
subdomain, membrane-binding surface, and kinase catalytic 
cleft, respectively [51]. Thus, the RH domain would serve 
as a docking site for GPCRs and help to control kinase acti-
vation via transient contacts of the RH bundle and kinase 
subdomains [26]. Despite all this accumulating knowledge, 
many questions remain regarding the determinants of GRK 
preferential targeting toward specific GPCRs, the mecha-
nisms triggering GRK2 kinase activity toward non-GPCR 
targets, and the control of the scaffolding roles of GRK2 
with different signaling partners. As discussed below, the 
ability of GRK2 domains to interact with activating factors 
might be modulated by association with additional partners 
and by protein modifications in response to other signaling 
networks, thus adapting the functionality of GRK2 to given 
cellular contexts.
GRK2 regulation: a precise spatio‑temporal 
control toward the right targets
Consistent with the complexity of its interactome, GRK2 
expression levels, activity, and subcellular location are 
tightly regulated (Fig. 2). The relative abundance, locali-
zation, and activation status of GRK2 in a given cellular 
context, would directly determine GPCR signaling and 
desensitization and its interaction with additional partners.
Post‑transcriptional GRK2 modifications shape 
kinase activity and target selectivity
GRK2 is phosphorylated by other kinases at different resi-
dues (Fig. 1), underlying complex cross-talk mechanisms 
between signaling pathways. GRK2 is modulated by second 
messenger-directed kinases downstream of many GPCRs. 
PKA phosphorylates Ser685 at the extreme C terminus of 
GRK2, enhancing its ability to bind to Gβγ and the activated 
GPCR, which facilitates homologous desensitization of Gs-
coupled GPCRs [52] and also of non-Gs-coupled GPCRs in 
a heterologous manner via GRK2 membrane targeting. Thus, 
selective phosphorylation of GRK2 by PKA in response to 
β-agonists augmented GRK2-Gαq association in response 
to acetylcholine stimulation of Gq-coupled M3 receptors, 
leading to inhibition of the Gq effector, PLCβ1 [53]. In turn, 
PKA phosphorylation of GRK2 is limited by the activity of 
PDE4 (phosphodiesterase-4), which settles a threshold for 
GRK2 modification by PKA in several contexts, avoiding 
inappropriate GRK2 membrane recruitment and receptor 
desensitization in non-stimulated cells [54, 55]. Phospho-
rylation by PKC on Ser29 led to an enhanced GRK2 cata-
lytic activity toward GPCRs but not soluble peptides [56]. 
In the light of structural data pointing that the integrity of 
the αN-helix of GRK2 (aa 1–30) with preservation of par-
ticular acidic residues is key for receptor interaction and 
phosphorylation [38, 40, 43], it is likely that phosphorylation 
of Ser29 improves kinase docking to GPCR by shaping prop-
erly the intrinsically disordered αN region (Fig. 1). Alter-
natively, Ser29 modification could exert allosteric effects in 
GRK2 activation guided by receptor interaction. In addition, 
phosphorylation of GRK2 by PKC on serine 680 has been 
reported to translocate the kinase to the cell membrane to 
desensitize the steroid hormone ecdysone-responsive GPCR 
(ErGPCR-2) [57].
In addition to PKA and PKC, GPCR stimulation can trig-
ger other kinase cascades to modify GRK2 in a feedback 
loop, altering its membrane localization and/or catalytic 
activity. c-Src phosphorylates GRK2 on tyrosine residues 
located in the αN-helix (Tyr13) and within the RH region 
(Tyr-86 and Try-92) [13, 58]. Remarkably, the catalytic 
activity of tyrosine-phosphorylated GRK2 is increased 
toward both soluble and membrane-bound substrates, sug-
gesting an allosteric effect on the kinase domain. Interest-
ingly, the active site tether (AST) that contributes to sta-
bilization of the nucleotide and phospho-acceptor binding 
sites in the active kinase makes contacts with the αN-helix. 
It has been proposed that the side chain of Tyr-13 is packed 
against the AST residue Val-477, forming a hydrophobic 
patch required for both receptor docking and allosteric acti-
vation (Fig. 1). The Y13A mutant shows reduced phospho-
rylation of peptides and receptors, which is consistent with 
a defective stabilization of the active state of GRK2 [40]. 
It is possible that the gain of a negative charge in Y13 in 
close proximity to acidic residues (D10, E476) involved 
in the interaction with the AST loop might alter receptor 
docking specificity and substrate preferences. Residues Y86 
and Y92 lie proximal to a hydrophobic interface formed 
between the RH domain and the kinase large lobe (Fig. 1), 
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and their phosphorylation could influence kinase domain 
closure, although this remains to be proved. Interestingly, 
activation of GRK2 by means of tyrosine phosphorylation 
can be achieved independently of GPCR stimulation and 
β-arrestin-mediated recruitment of c-Src [13]. PDGFRβ 
itself phosphorylates and activates GRK2, which then 
serine-phosphorylates and desensitizes PDGFRβ in a nega-
tive feedback loop [59]. EGFR also directly phosphorylates 
GRK2 on the reported tyrosine residues, allowing mem-
brane recruitment and enhanced GRK2-mediated desensi-
tization of opioid receptors [60] or dopamine D3 receptors 
[61] in a EGF-dependent manner. Even membrane receptors 
devoid of catalytic activity can also engage cytosolic tyros-
ine kinases to activate GRK2. TCR-activated c-Src leads to 
inducible tyrosine phosphorylation of GRK2 and stimula-
tion of GRK2-dependent CXCR4-Ser-339 phosphorylation 
and TCR-CXCR4 complex formation. Such GRK2-mediated 
complex drives the PI3Kγ-dependent recruitment of PREX1, 
which is required for full cytokine secretion during T cell 
activation [62].
In addition to increasing GRK2 activity, tyrosine phos-
phorylation within the RH domain also enhances the interac-
tions of GRK2 with other proteins such as Gαq upon mus-
carinic receptor M1 stimulation [63] or the scaffold protein 
GIT1 in response to integrin receptor activation ([64], see 
also below). Thus, tyrosine phosphorylation of GRK2 is a 
key event in receptor transactivation that endows this kinase 
with novel catalytic and non-catalytic effector capabilities.
Fig. 2  Multiple regulatory mechanisms allow precise spatio-temporal 
control of GRK2 levels and functionality. Multiple layers of modula-
tion converge to control GRK2 dosage, localization, phosphorylation 
activity, and scaffolding functions toward both GPCR and non-GPCR 
partners in response to extracellular signals. Different signals act 
through transcription factors to modulate transcription of the GRK2 
gene (ADRBK1). GRK2 transcript levels are finely tuned in diverse 
settings by miRNAs or via modulation of transcript translation by 
different mechanisms. Interaction with chaperones (Hsp90) guides 
GRK2 folding and maturation. A diverse set of cellular inhibitors and 
activators controls the catalytic activity of GRK2 and its context-spe-
cific repertoire of substrates or interactors. Catalytic activity can be 
influenced by protein–protein interactions in a positive (Gβγ, GPCR) 
or negative (caveolin, calmodulin, α-actinin) manner. Similarly, phos-
phorylation by distinct kinases (PKA, PKC, ERK, c-Src, RTKs) or 
S-nitrosylation also modifies kinase activity and substrate selection. 
Besides regulating GRK2 activation status, these factors contribute 
to compartmentalization of GRK2 activity by docking the protein in 
specific subcellular locations, in close proximity with particular sub-
strates or partners. Finally, GRK2 degradation irreversibly modulates 
GRK2 activity and levels via ubiquitination by several ligases and 
proteolytic clearance by the proteasome or calpain proteases. Protein 
decay is frequently turned on by the same modifications triggering 
changes in GRK2 catalytic activity, as many phosphorylation sites on 
GRK2 behave also as enabling signals or phoshodegrons for ligases 
and proteases. See text for details
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Different proline-directed kinases, which play critical 
roles in cell cycle, stress responses, and survival or meta-
bolic control, converge in phosphorylating GRK2 on Ser-
670. Mitogen-activated protein kinases ERK1/2 and p38 
have been reported to phosphorylate this residue in response 
to GPCR [65] or TLR4 [66] activation, and cyclin-dependent 
kinase, CDK2–cyclin A, phosphorylates GRK2 during cell 
cycle progression [67]. In a setting of ischemia, PI3K/AKT 
pathway activation promotes S670 phosphorylation through 
an unidentified kinase [68]. The S670 residue lies within the 
Gβγ-binding domain of GRK2 (Fig. 1), and its phosphoryla-
tion strongly impairs the interaction of GRK2 with Gβγ sub-
units, thereby inhibiting kinase translocation to the plasma 
membrane and kinase activity toward membrane-located 
substrates [69, 70]. Phosphorylation of GRK2 on S670 might 
alter potential paths of GRK2 allosteric activation. The RH 
domain has been proposed to act as an allosteric transducer 
domain, since the interaction of the α10 helix (aa 511–515) 
with the small kinase lobe may play regulatory roles similar 
to the SH2-catalytic domain linker in c-Src [27]. Close to 
this RH–kinase small lobe interface, the terminal subdomain 
of the RH region interacts with a cluster of residues in the 
PH domain that binds directly to Gβγ. This suggests that 
S670 phosphorylation may transmit structural alterations 
affecting the conformation of the catalytic domain and thus 
activity. Interestingly, this modification at the C terminus 
promotes a switch in GRK2 substrate specificity, fostering 
the acquisition of a distinctive competence to phosphorylate 
HDAC6 [71], also see below). In addition, GRK2 phospho-
rylation at S670 by MAPK disrupts GRK2 interaction with 
GIT1 [64], whereas it is required for kinase localization to 
the mitochondrial outer membrane via enhanced interaction 
with the chaperone Hsp90 [72]. In summary, S670 phospho-
rylation appears to play a central role in the modulation of 
GRK2 functional features such as catalytic activity toward 
GPCRs and non-GPCR substrates, subcellular localization, 
and the ability to interact with protein partners (see Fig. 2).
Regarding other types of post-translational modifica-
tions, GRK2 can undergo S-nitrosylation of Cys residue 
340 within its catalytic domain, leading to the inhibition of 
kinase activity toward GPCRs [73], as well as ubiquitination 
of lysine residues related to the control of GRK2 turnover 
(see below).
GRK2 is present in different subcellular pools
GRK2 was initially identified as a cytosolic protein able to 
translocate to the plasma membrane upon GPCR stimula-
tion [4, 13]. However, a significant amount of GRK2 was 
reported to be associated with internal microsomal mem-
branes by means of electrostatic interactions between 
the N-terminal region of the kinase (RH domain) and an 
unknown protein which is an integral component of the 
microsomal membrane [74, 75]. Interestingly, the interac-
tion of GRK2 with the unidentified anchoring protein leads 
to inactivation of the bound kinase, what can be reverted by 
stimulation of endogenous heterotrimeric G proteins [75]. 
On the other hand, the C terminus of GRK2 directly binds to 
clathrin, an interaction that may facilitate the internalization 
of certain GPCRs, resulting in the co-localization of GRK2 
with β-adrenergic receptors in endosomes during agonist-
induced receptor internalization [76–78].
GRK2 activity is inhibited upon interaction with several 
cellular partners such as calcium-binding proteins, α-actinin, 
Hsp90, and caveolin (reviewed in [79]). For instance, calmo-
dulin interacts with GRK2 at sites located at both the N- and 
C-terminal domains of the kinase and directly inhibits its 
activity [80]. Of note, these regulatory partners may act as 
adapters or anchoring factors, helping to preserve different 
pools of inactive kinase and to guide catalytic or scaffold-
ing activities of GRK2 toward particular substrates (Fig. 2). 
In this regard, the association of the kinase with caveolin-1 
or -3 inhibits GRK2-mediated phosphorylation, suggesting 
that caveolins may play a role in controlling basal GRK2 
activity [81]. However, since caveolins serve as scaffolds 
for a variety of signaling molecules including GPCRs, dif-
ferent MAPKs, and G proteins helping to compartmentalize 
their signaling, the association of the GRK2 with caveolin 
may also facilitate the interaction of this kinase with other 
signaling or regulatory molecules. In this regard, caveolin 
and GRK2 together regulate eNOS in sinusoidal endothe-
lial cells. β2AR stimulation triggers the association of both 
proteins, and β-agonist-induced Tyr-14 phosphorylation of 
caveolin is required for such association. Interestingly, the 
GRK2–caveolin complex leads to eNOS recruitment and 
decrease of AKT-mediated eNOS-Ser1177 phosphoryla-
tion, resulting in blockade of NO production [82]. Of note, 
GRK2 has been reported to interact directly with AKT in 
liver sinusoids, thus inhibiting AKT-mediated phosphoryla-
tion of substrates [83], but whether such regulatory effect is 
mediated by caveolin has not been addressed.
Mitochondrial and nuclear pools of GRK2 have also 
been reported. Although GRK2 does not display a canonical 
nuclear localization sequence as GRK5 does [84], high lev-
els of both GRK isoforms have been detected in the nuclear 
fraction of neuronal cells from the striatum [85]. Interest-
ingly, like GRK5 [86], GRK2 has been found in centrosomes 
and was suggested to play a critical role in mediating EGF-
dependent separation of duplicated centrosomes, although it 
has no role in centrosome duplication or microtubule nuclea-
tion [87].
GRK2 has also been shown to interact with heat shock 
protein 90 (Hsp90), a known mitochondrial chaperone [88], 
to localize in the mitochondria and to regulate mitochondrial 
biogenesis when accumulated inside this organelle [89]. 
GRK2 mitochondrial levels increase during inflammation 
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or upon LPS stimulation in macrophages, helping to facili-
tate biogenesis and to restore mitochondrial function [90]. It 
has also been proposed that GRK2 localizes to mitochondria 
in HEK293 cells upon ionizing radiation and that that this 
kinase plays a protective role in this context by regulating 
mitochondrial fusion through interaction and phosphoryla-
tion of Mitofusin-1 and -2 [91]. On the contrary, in the con-
text of ischemia reperfusion in vivo and in cultured myo-
cytes, GRK2 localizes to mitochondria via ERK-mediated 
phosphorylation of GRK2 at Ser670 and Hsp90 binding, and 
contributes to mitochondrial-dependent pro-death signaling 
[72], increases superoxide levels, and impairs fatty acid oxi-
dation and ATP production [92]. A better understanding of 
the stimuli triggering GRK2 localization to mitochondria 
and the impact of GRK2 dosage on mitochondrial function 
in different cell types and pathophysiological contexts is 
needed.
Control of GRK2 protein turnover
Protein degradation has emerged as the main mechanism 
for triggering rapid local changes of GRK2 functionality 
(Fig. 2). GRK2 is a short-lived protein and the chaperone 
function of Hsp90 plays a critical role in GRK2 protein sta-
bility and maturation in most cell types. Impaired Hsp90 
activity results in degradation of GRK2 in a proteasome-
mediated manner [88]. Moreover, GRK2 is rapidly degraded 
upon GPCR activation in an ubiquitin and proteasome-
dependent manner [93]. Ubiquitination of GRK2 at the 
N-terminal lysine residues K19, K20, K30, and K31 marks 
the protein for its proteasome-dependent degradation in 
basal and agonist-stimulated conditions [94]. Interestingly, 
both GRK2-mediated phosphorylation of ligand-occupied 
receptors and β-arrestin engagement of the receptor com-
plex are early common events triggered by GPCR activation, 
and both were found to be necessary for agonist-induced 
proteolysis of GRK2. Further studies revealed that cSrc-
dependent phosphorylation of GRK2 was instrumental in 
this process [95]. Moreover, ERK-mediated phosphorylation 
of GRK2 at Ser670 also can promote its degradation [65]. 
Although both c-Src- and ERK-mediated phosphorylation of 
GRK2 can target GRK2 for degradation independently, ERK 
preferentially phosphorylates once GRK2 has been previ-
ously phosphorylated on tyrosine residues by c-Src [65]. 
The main E3 ligase implicated in GRK2 turnover by the 
proteasome pathway is Mdm2 [94]. Further characterization 
of the Mdm2-dependent GRK2 degradation revealed that 
upon GPCR activation, Mdm2 action on GRK2 is medi-
ated by previous GRK2 phosphorylation on Ser670 but not 
by tyrosine phosphorylation, although c-Src phosphoryla-
tion facilitates the subsequent phosphorylation of GRK2 by 
MAPK [96].
Arrestins are known to recruit c-Src, ERK, and Mdm2 
to the vicinity of activated GPCRs [97, 98] and these scaf-
fold molecules are required to facilitate sequential GRK2 
phosphorylation and Mdm2-mediated degradation upon 
GPCR activation. However, in the absence of GPCR activ-
ity, β-arrestins do not participate in the Mdm2-mediated 
regulation of basal GRK2 turnover, but instead compete 
with GRK2 for Mdm2 and suppress basal GRK2 degra-
dation [96]. In basal conditions, c-Src is able to mediate 
Mmd2-independent GRK2 degradation, although the E3 
ligase implicated in this process remains to be elucidated. 
Thus, β-arrestins play a coordinating role recruiting kinases 
and/or ubiquitin ligases to GRK2 in the basal condition or 
upon activation of GPCRs, regulating GRK2 turnover via 
different pathways. Adding more layers of complexity, it is 
also worth noting that Mdm2 phosphorylation by AKT in 
response to stimulation of growth factor receptors such as 
IGFR leads to E3 ligase translocation to the nucleus, result-
ing in enhanced stability of cytoplasmic GRK2 and higher 
expression levels [94].
Notably, the phosphorylation status also affects GRK2 
stability in a cell cycle context, thus governing the fluctua-
tions in kinase levels taking place during cell cycle progres-
sion. Phosphorylation of GRK2 at Ser670 by CDK2–cyclin 
A and the subsequent binding of the prolyl-isomerase Pin1, 
are required for transient GRK2 proteasome degradation 
during the G2/M transition [67], although the E3 ligase 
involved was not identified. As Mdm2 protein expression 
is also cell cycle regulated, with a prominent accumulation 
through G2/M, it is tempting to suggest that this ligase plays 
a role in downregulating GRK2 in this context, but the con-
tribution of other ligases cannot be excluded.
It has been reported that Gβ subunits have a non-canon-
ical function acting as substrate recruiters for Cul4-RING 
ubiquitin ligases [99, 100]. In particular, a member of the 
Gβ family, Gβ2, specifically targeted GRK2 for ubiquitina-
tion and degradation by the cytosol-enriched DDB1-Cul4A-
ROC1 ligase. Curiously, agonist stimulation of β2AR caused 
delayed turnover of GRK2 and up-regulation of global 
kinase levels in HEK293 cells through a mechanism involv-
ing PKA-mediated phosphorylation of DDB1 and disruption 
of Gβ2 binding to DDB1-Cul4A ligase. This mechanism 
of feedback regulation and GRK2 stabilization evoked by 
β2AR stimulation appears to be in conflict with previously 
published data demonstrating GPCR-(including β2AR)-
induced GRK2 degradation [101]. Moreover, while these 
authors suggest that DDB1-Cul4A-ROC1 ligase is the physi-
ological ligase impaired in cardiac hypertrophy, heart failure 
or hypertension, conditions linked to adrenergic overdrive 
and excessive PKA activation, others have demonstrated 
that defective cardiac Mdm2 led to a significant increase in 
GRK2, resulting in severely impaired cardiac function [102]. 
Therefore, further studies are needed to define the main E3 
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ligase responsible of keeping steady-state levels of GRK2 
in defined pathological contexts. Interestingly, Cul4-DDB1 
is also recruited to the non-classical GPCR Smo through Gβ 
to promote internalization and degradation of Smo receptor 
and GRK2 itself, while in the presence of Hedgehog, PKA 
is activated and Cul4-DDB1 is dissociated from Smo, allow-
ing receptor and GRK2 accumulation for signal transduction 
[99]. Based on this finding, it has been suggested that this 
ubiquitin ligase could play a broader role in GPCR regula-
tion, being recruited as active receptors by receptor-bound 
GRK2-Gβ complexes to trigger their internalization, in a 
similar way as GPCR-bound β-arrestins bring Mdm2 and 
other ubiquitin ligases for GRK2 and receptor ubiquitination.
On top of that, other protein degradation machineries can 
participate in the control of GRK2 levels. Inappropriate cal-
pain activation has been implicated in various disease states 
including cerebral and heart ischemia, muscular dystrophies, 
and chronic inflammation [103]. Proteasome-independent 
GRK2 downregulation takes place in several of these set-
tings. In arthritis and in active relapsing–remitting multiple 
sclerosis (MS) or secondary progressive MS [104], inflam-
matory cytokines trigger oxidative stress-induced GRK2 
down-regulation through the calpain proteolytic pathway. 
Many substrates of calpains exhibit a PEST region, rich 
in proline (P), glutamic acid (E), serine (S), and threonine 
(T). GRK2 bears a putative PEST region (aa 591–615) and 
purified calpain is capable to promote partial proteolysis of 
recombinant GRK2 in a calcium-dependent manner in vitro, 
suggesting that the cleavage may occur between aa 677 and 
678 of GRK2 [105]. Of note, the existence of a cAMP-
dependent protein kinase A (PKA) phosphorylation site 
(S685) in GRK2 close to the calpain cleavage site raises the 
possibility of a regulatory interplay between protein phos-
phorylation and calpain-mediated degradation of GRK2 in 
the context of myocardial and cerebral ischemia, which are 
conditions characterized by a potent activation of PKA.
GRK2 regulation at the transcriptional level
Although regulation of protein stability appears to play a 
major role in determining GRK2 dosage, changes in mRNA 
levels of GRK2 have been noted in several pathological con-
ditions, including hypertension, heart hypertrophy, and heart 
failure [18, 106], in the acute stage of infectious diseases, 
such as pneumonia and sepsis [107], or in tumoral patholo-
gies [19]. However, relatively little is known regarding the 
mechanisms controlling GRK2 promoter activity and tran-
script stability or other layers of control, such as regulation 
by non-coding RNAs or RNA-binding proteins (Fig. 2).
Several SNPs within the promoter of the ADRBK1 
gene and in non-coding regions have been identified. The 
rs4930416 and rs1894111 SNPs were found to be associated 
with differential antihypertensive drug response in black 
and white patients [108]. Several of these SNPs within the 
gene were found to be in linkage disequilibrium (LD) in the 
black population, what could indicate that some of these 
SNPs may impact gene regulatory sequences. Although 
the influence of non-coding SNPs in GRK2 expression has 
not been addressed, in silico analysis showed that they may 
yield unique transcriptional factor-binding sites, resulting in 
potential changes in ADRBK1 regulation [109].
Analysis of the human breast cancer TCGA database 
shows that GRK2 mRNA is expressed at statistically sig-
nificantly higher levels in tumor cells compared to normal 
breast tissue [110], which is in line with increased protein 
levels detected in breast cancer patients [111]. Interest-
ingly, the ADRBK1 gene is located at the 11q13.2 band and 
is identified as part of the amplicon 11q13 which undergoes 
amplification at high frequencies in breast tumors, showing 
a strong association between copy number status and gene 
expression level [112].
In vascular cells, phorbol esters (PMA), as well as the 
activation of Gαq or α1-adrenergic signaling pathways, 
increased GRK2 promoter activity, consistent with increased 
GRK2 protein in settings of physiological vasoconstric-
tion and hypertrophy, whereas pro-inflammatory cytokines 
had the opposite effect [13, 113]. Mitogenic stimulation 
led to increased GRK2 mRNA expression in T cells [114] 
and increased GRK2 protein levels in different cell types 
[111, 115]. However, the identity of transcription factors 
downstream of such stimuli that are responsible for GRK2 
mRNA alterations is largely unknown. It has been reported 
that several regions of the GRK2 promoter match with the 
response element of EGR-1, a transcription factor stimulated 
by PMA, and usually engaged in responses stimulated via 
Gαq-coupled GPCRs. EGR-1 binds to GRK2 promoter and a 
novel G(-43)A polymorphism (rs182084609) was identified 
within one of these EGR-1 binding sites regions, leading to 
a greater increase in EGR-1-induced transcriptional activ-
ity in the promoter bearing the G(-43) allele vs. the A(-43) 
allele [116].
Emergent findings point to a potential reciprocal interplay 
between GRK2 and the circadian rhythms machinery, based 
on the effect of GRK2 on the Period 1 and 2 (PER1/2) nega-
tive clock regulators [117, 118]. GRK2 acts post-translation-
ally on PER1 and PER2, physically binding to both proteins 
and promoting the phosphorylation of PER2, what impairs 
the trafficking of PER proteins into the nucleus and causes 
sustained Per2 expression, disrupting circadian rhythms. 
Interestingly, the mRNA levels of GRK2 in different tis-
sues (such as colon and liver) appear to oscillate in a circa-
dian manner as shown in the CircaDB database (http://circa 
db.hogen eschl ab.org/query ), suggesting that GRK2 may be 
a clock-controlled gene.
MicroRNAs (miRNAs) are short non-coding RNAs 
(ncRNAs) that are emerging as important modulators of the 
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expression of multiple genes via degradation of mRNA or by 
preventing translation of target genes. Increasing evidence 
demonstrates that long non-coding RNAs (lncRNAs) also 
regulate gene and protein expression via transcriptional and 
post-transcriptional processes [119, 120]. However, little 
is known about the participation of these factors in GRK2 
regulation. It has been described that miR-K3, a Kaposi’s 
sarcoma-associated herpesvirus (KSHV) miRNA, facilitates 
cell migration and invasion via activation of the CXCR2/
AKT pathway by repressing GRK2 expression [121], point-
ing to a role of GRK2 in suppressing KSHV-associated 
tumor progression. Besides migration and invasion, miR-K3 
also enhances KSHV latency and angiogenesis by target-
ing GRK2 and inhibiting its expression [122]. The lncRNA 
UCA1 increases the ability of gastric cancer cells to metas-
tasize by regulating the stability of GRK2 protein via the 
promotion of Cbl-c-mediated ubiquitination and degradation 
of GRK2, adding another level of complexity to the regula-
tion of the expression of this kinase [123]. The identification 
of miRNAs and lncRNA that are able to control GRK2 dos-
age in different conditions is an interesting future research 
avenue.
Revisiting paradigms on GPCR‑mediated 
GRK2 activation
The conventional flowchart in GPCR homologous desen-
sitization starts with agonist receptor occupancy and cou-
pling of the activated receptor with heterotrimeric G pro-
teins which dissociate into Gα subunits and Gβγ dimers 
for downstream signal transduction. Released Gβγ subu-
nits and plasma membrane phospholipids co-recruit cyto-
plasmic inactive GRK2 into the vicinity of ligand-bound 
GPCR, and they together allosterically activate the kinase 
for receptor phosphorylation, followed by high affinity asso-
ciation of β-arrestins with the phosphorylated receptor [2, 
4]. Therefore, this paradigm implies that: (1) GRK2 exclu-
sively phosphorylates GPCR in their agonist-bound state; 
(2) G protein activation and hence GRK2-Gβγ complex 
formation is mandatory for receptor phosphorylation; (3) 
β-arrestin engagement only occurs upon GRK2-mediated 
GPCR phosphorylation. However, recent functional and 
structural data have called into question these principles. For 
instance, GRK2 can be docked directly to some GPCRs in a 
Gβγ-independent manner [124]. By using altered dopamine 
D2R receptors, prone to preferentially stimulate G proteins 
D2R[Gpro] or recruit β-arrestins D2R[βarr], in combina-
tion with biased ligands directing wild-type D2R toward 
β-arrrestin in a GRK2 dosage-dependent manner, these 
authors demonstrated that G protein-independent recruit-
ment of GRK2 is key for preferential D2R-biased signaling 
to β-arrrestin. GRK2 bound to D2R in such conditions is 
active toward the receptor and its phosphorylation promotes 
β-arrestin mobilization. The fact that GRK2 can be recruited 
to wild-type D2R receptors with a rather modest contribu-
tion from Gβγ-mediated kinase translocation poses the 
question of how kinase activation occurs in the presence of 
different receptor conformations, and whether the catalytic 
competence of GRK2 in such GPCR-only complex is the 
same than in the presence of Gβγ subunits (for instance, the 
extent and identity of phosphorylated residues in D2R[βarr] 
and D2R[Gpro] could be different).
Other studies support the notion that GRK2 docking to 
GPCRs and activation can be uncoupled from Gβγ-mediated 
recruitment. Data obtained with the catalytically inactive 
GRK2-K220R mutant suggested that kinase activity was 
dispensable for plasma membrane and GPCR recruitment 
since this mutant is able to interact with Gβγ subunits. Thus, 
reduced efficacy of β-arrestin recruitment in the presence 
of the GRK2-K220R mutant was ascribed to the lack of 
GPCR phosphorylation by a receptor-bound inactive GRK2. 
However, pharmacological inhibition of GRK2 with the 
small molecule Cpmd101 yields contradictory results when 
compared to GRK2-K220R in receptor recruitment assays. 
Neither dopamine D2R interaction with Cmpd101-bound 
GRK2 nor with K220R mutant protein is affected [124], 
while the interaction of GRK2 with MOR opioid receptor is 
fully prevented by Cmpd101 [125]. It seems that for some 
GPCRs, GRK2 must be in a pro-active configuration for 
interaction and already folded in the context of a K220R 
mutation, which only impedes phosphotransferase activity. 
In contrast, the inactive conformation of GRK2 stabilized by 
Cpmd101, that impedes the closure of kinase domain [126], 
is competent to interact with other GPCRs, suggesting that 
concurrent events can contribute differently in the recruit-
ment of active vs. non-active GRK2 (Gβγ-preassembled 
complexes, interacting partners, post-transcriptional modi-
fications). This diversity in GRK2 receptor docking might 
have implications, for instance, in whether Cpmd101 can 
prevent scaffolding roles of GRK2 in the desensitization of 
Gαq-coupled receptors.
Overall, these results suggest that GRK2 (in either active 
or inactive forms) could interact with GPCRs in different 
conformational states, and that different paths of allosteric 
activation could trigger GRK2 catalytic activity.
As discussed in the previous sections, the control of 
GRK2 activation involves dynamic interactions of its dif-
ferent domains and regions with GPCR, Gβγ, and lipids and 
among themselves, ultimately leading to rearrangement of 
the AST loop and kinase domain closure, and this activation 
process can also be influenced by post-translational modi-
fications in the N-terminal RH domain and the C-terminal 
PH domain of the kinase (Fig. 1).
In addition to AST, the first 20 amino acids of GRKs are 
also quite disordered and, based on recent crystallographic 
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studies on GRK6, it has been proposed that this region may 
adopt an extended α-helix conformation that, in addition to 
serving as an interface with GPCR, would pack against the 
kinase small lobe and the AST, contributing to the stabiliza-
tion of active conformation, and induce allosteric activation. 
Thus, activated GPCRs could stimulate GRKs by ordering 
the N terminus and AST regions. Furthermore, the N-ter-
minal region of GRKs could play a role in kinase domain 
closure, even independently of receptors [41].
Remarkably, both AST and the αN-helix regions differ 
broadly in their sequences among different GRKs, suggest-
ing that they might convey diverse ways of allosteric activa-
tion. The identification of key residues for receptor docking 
and/or kinase allosteric activation in the N-termini of GRKs 
may help to understand GPCR phosphorylation preferences 
by GRKs or how GRK2 might be allosterically activated by 
non-target GPCRs to trigger phosphorylation of additional 
substrates. Mutational analysis combined with BRET-based 
protein interaction and kinase phosphorylation assays has 
allowed the identification of key surface-exposed residues 
(L4, V7, L8, V11, S12) in the αN-terminal helix of GRK2 
that comprises a direct hydrophobic GPCR docking site able 
to provide GPCR selectivity (Fig. 1). For instance, mutant 
GRK2-L4A is impaired in α2AR but not β2AR interaction, 
while other mutations strongly increased kinase recruit-
ment to α2AR [38, 40]. Differential impact of αN residues 
in GRK2-mediated phosphorylation of GPCRs and soluble 
peptides also indicates that some positions facing either 
the small lobe (A16, M17) or the AST loop (D10, Y13) 
(see Fig. 1), contribute to induce active conformations with 
different catalytic outcomes. Receptor docking sites on the 
αN (such as D3 or L4) also relay allosteric activation, as 
receptor-induced phosphorylation of soluble peptides is 
impaired when theses residues are mutated. Interestingly, 
these meticulous mutational studies also suggest that recep-
tor kinase docking can be uncoupled from receptor-induced 
kinase allosteric activation. This is exemplified by the 
mutant GRK2-D10A which showed compromised catalytic 
activity toward soluble peptides and several GPCRs, despite 
its efficient docking, pointing to a poor active conformation 
[38, 40]. Intriguingly, this mutant fulfills phosphorylation 
of tubulin, while other αN mutants are competent to phos-
phorylate receptors but not soluble peptides. These findings 
suggest that flexibility at the interface of αN residues and the 
AST loop may confer biased kinase activity. Phosphoryla-
tion of GRK2 or interacting partners affecting the αN region 
of GRK2 may not only quantitatively regulate the catalytic 
activity (as phosphorylation by PKC on S29 in the context 
of GPCR or peptide phosphorylation) but could qualitatively 
enable catalytically active conformations toward specific tar-
gets. This scenario becomes more plausible as the list of 
non-GPCR and non-membrane substrates of GRK2 grows 
in number and heterogeneity (see Table 1), raising questions 
about how closure of kinase domain is achieved in a recep-
tor- and Gβγ/phospholipid-independent manner.
Examples of context‑specific GRK2 
multifunctionality
Multifunctional roles of GRK2 in the modulation 
of pain perception and chronicity
Pain hyper-sensitivity and chronic pain are disabling condi-
tions conditioned by genetic and environmental factors. In 
the acute phase of pain, inflammatory mediators released 
by damaged tissues and catecholamines secreted by sympa-
thetic afferents and adrenal gland under stress provoke sensi-
tization of nociceptors to noxious stimuli in a process known 
as hyperalgesia, which in the short term is beneficial for the 
organism. Hyperalgesic factors directly stimulate GPCRs in 
nociceptor cells such PGE2 receptor (EP2) or β2AR among 
others, which activate cAMP and PKA-dependent pathways 
that reduce hyperpolarisation-activated inward currents and 
augment voltage-activated Na currents, thus increasing the 
frequency of action potential firing [127]. Although inflam-
matory stimuli or adrenergic stress typically result in short-
lasting hypersensitivity, they can also evoke a priming effect 
that triggers more pronounced and persistent sensitization 
to subsequent hyperalgesic challenges or to noxious stimuli, 
thus contributing to chronic pain.
In acute hyperalgesia, GPCR desensitization curtails 
cAMP and PKA activation by either conventional GRK2-
dependent receptor phosphorylation (β2AR) or by undefined 
GRK2-independent mechanisms (EP2) [128]. Notably, even 
though long-term exposure to PGE2 causes desensitization 
of receptor-mediated cAMP production and activation of 
PKA, PGE2-induced pain sensitization is not downregu-
lated, i.e., successive challenges result in stronger and more 
prolonged pain responses [129]. Interestingly, inflammation 
produces a decrease in GRK2 levels in nociceptors, and 
reduction of GRK2 levels in peripheral sensory neurons 
by a variety of approaches enhanced intensity and duration 
of epinephrine- or PGE2-induced mechanical hyperalgesia 
[130–134]. Conversely, delivery of extra GRK2 prevented 
the prolongation of PGE2-induced hyperalgesia in primed 
mice [135]. These data strongly support that GRK2 is key 
in the control of pain priming and chronicity.
Transient hyperalgesia is a PKA-dependent process, while 
persistent pain is PKA independent and involves PKCε/
ERK-mediated pathways that ultimately phosphorylate 
transducer proteins and ion channels in peripheral sensory 
terminals, leading to their enhanced activation [136]. PKCε 
is a key intracellular mediator implicated in the onset of 
mechanical, thermal, or inflammatory hyperalgesia, and in 
transition from acute to chronic inflammatory pain. In naïve 
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animals, acute PGE2 and epinephrine activate the cAMP-
PKA pathway [131, 132, 137], while in primed animals and 
cellular models, agonist-induced cAMP increase results in 
activation and membrane translocation of Epac1, which 
stimulates PKCε via phospholipases, PLC and PLD [138]. 
Importantly, low levels of GRK2 in nociceptors switch 
EP2- and β2AR-induced signaling from a protein kinase 
A-dependent to a PKCε-dependent pathway [134]. GRK2 
basally interacts with Epac1 and GRK2-mediated phos-
phorylation of Epac1 on S108 precludes Rap1 and PKCε 
activation, without apparently affecting the cAMP binding 
to Epac1 or cAMP-Epac1 activation of Rap1 [139]. Thus, 
GRK2 restrains the ability of Epac1 to stimulate local targets 
by means of altering the regulatory domain that mediates the 
subcellular localization of Epac through binding to phospha-
tidic acid in the plasma membrane.
Opposed to the role of inflammatory or adrenergic recep-
tors in hyperalgesia, stimulation of opioid receptors in the 
cell bodies in the dorsal root ganglion (DRG) and on primary 
afferent neurons triggers analgesia. Opioids act on differ-
ent types of GPCRs (MOR, DOR, and KOR) coupled to 
Gi/o proteins that reduce the cAMP levels and PKA activ-
ity, thus causing nociceptor hyperpolarization and decreased 
neuronal excitability. Interestingly, GRK2 can trigger rapid 
phosphorylation and desensitization of MOR [125], promote 
downregulation of KOR in diabetic conditions [140] and in 
response to specific opioid ligands [141] or enable internali-
zation and recycling of DOR [142]. A recent report has also 
indicated that phosphorylation of GRK2 at S670 is higher 
in female that in male mice in both ventral striatum and in 
spinal cord, leading to decreased KOR-mediated G protein 
signaling to ERK and defective agonist-induced analgesia 
in female animals, a gender difference that can be rescued 
by inhibition of GRK2 catalytic activity in females [143]. 
Interestingly, chronic pain is more common in women. 
Nociception itself is influenced by sex due to differential 
cortical processing of pain-related stimuli [144], whereas 
the sensitivity of peripheral sensory neurons is apparently 
also under the influence of estrogens [145], by mechanisms 
involving rapid non-genomic signaling in nociceptors via the 
plasma membrane estrogen-sensitive GPCR GPR30 (poten-
tial target of GRK2) and palmitoylated-estrogen receptors, 
ERα and ERβ [146]. These results open the possibility that 
gender-specific differences in GRK2 expression and/or phos-
phorylation status might underlie gender differences in pain 
perception.
In summary, both GPCR- and non-GPCR-related func-
tions of GRK2 play a role in the control of pain. It would be 
of interest to determine whether changes in GRK2 dosage 
taking place in inflammatory pain conditions differentially 
affect the role of this kinase in the modulation of the EPAC1 
pathway and in the control of both hyperalgesic and analge-
sic GPCR signaling.
Catalytic and scaffold roles of GRK2 modulate 
proliferation and cell cycle progression
The driving role in the coordination of cell growth and 
division has been traditionally ascribed to tyrosine kinase 
growth factor receptors [147]. However, it is now undisputed 
that GPCRs also are relevant players in the regulation and 
activation of cellular growth pathways [148]. Many potent 
mitogens such as lysophosphatidic acid (LPA), thrombin or 
prostaglandins stimulate cell proliferation through GPCR 
activation [148, 149]. The complex interactome of GRK2 
and its ability to regulate both GPCRs and RTKs respond-
ing to a vast diversity of external cues (nutrients, stress and 
metabolic hormones, growth factors) make this protein a 
potential signaling integrator linking cell proliferation to 
environmental constrains. The varied mechanisms underly-
ing the role of GRK2 in GPCR and RTK-triggered MAPK 
cascades have been recently reviewed [12].
In addition to tuning mitogenic, growth arresting, and sur-
vival signaling pathways, emerging evidence indicates that 
GRK2 also modulates the cell cycle and division machinery. 
GRK2 appears to contribute to proper and timely progres-
sion of G1/S and G2/M transitions of the cell cycle by tar-
geting specific components of the cell division machinery 
[67]. Reduction of BrdU-positive cells in GRK2 knockdown 
zebrafish embryos and in model cell lines [150] point to a 
role of GRK2 in G1/S. During G1, cells synthesize mRNA 
and proteins for mass and volume increment before enter-
ing into the S phase. This process is controlled and limited 
by growth factors, the extracellular matrix, and cell–cell 
contacts, as well as by stress conditions [151]. Also, cell 
division is not allowed until a defined cell homeostatic size 
is achieved; otherwise dividing cells will become smaller. 
Cells can assess size thresholds based on protein synthesis 
rates, which are influenced by nutrient and growth factor 
signaling [152]. Cyclins and other CDK activators such 
as Cdc25 phosphatase might link signaling routes of siz-
ing with cell cycle transitions at G1/S and G2/M. In this 
context, the influence of GRK2 in nutrient sensing and/or 
the intensity of growth signaling pathways might be key for 
cell division. For increasing cell size, ribosomes and the 
translational machinery need to accumulate, and phospho-
rylation of the ribosomal S6 protein by S6 kinase (S6 K) 
is important in this process. S6 K is regulated directly by 
mTORC1, which is a master sensor of nutrients and a trans-
lational activator of cell cycle initiators such as cyclin D 
[153]. Interestingly, positive correlations between mTOR 
activity and GRK2 protein levels have been reported in dif-
ferent cellular models [154, 155], although whether GRK2 
is an upstream modulator of mTORC1 or a downstream 
effector is not known. It has also been suggested that the 
mTORC1 pathway is modulated by GPCRs through REDD1 
(regulated in development and DNA damage responses), a 
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stress-responsive factor that binds to and inhibits mTORC1. 
Diverse GPCRs known to be regulated by GRK2 recruit 
REDD1 to the plasma membrane, thus relieving mTORC1 
inhibition [156]. Therefore, GRK2 may influence (either at 
the receptor or post-receptor level) cell growth during the 
gap phases of the cell cycle via mTORC1 pathway modula-
tion. On the other hand, GRK2 phosphorylates the riboso-
mal component P2 in a β2AR-dependent way, fostering the 
translational activity of ribosome 60S subunits [157], and 
is known to bind and phosphorylate IRS1, other relevant 
modulator of cellular proliferation [18, 158], thus providing 
other potential avenues for GRK2-mediated control of cell 
proliferation during the G1 phase.
The complex mechanisms leading to transient GRK2 pro-
tein downregulation during G2/M (as detailed in a previous 
section), together with the delayed progression in this phase 
when GRK2 is improperly stabilized [67] and its localization 
at the centrioles and pericentriolar matrix in both interphase 
and during centrosome separation [87], suggest that GRK2 
participates in processes that help to prepare the cells for 
entry into the mitosis phase [159]. During G2, the so-called 
“centrosome disjunction” process is mediated by the NIMA-
related kinase Nek2, which phosphorylates C-Nap1 and 
rootelin to allow centrosomes to separate in a kinesin (Eg5)-
mediated manner and form the two poles of the mitotic spin-
dle [160]. Such centrosome separation must be precise, and 
its improper timing or length may result in defective mitotic 
spindles [161, 162]. Of note, GRK2 is involved in the timely 
regulation of this process by directly phosphorylating Mst2 
kinase (an upstream activator of Nek2) in response to EGF 
receptor stimulation during the early course of G2 [87], thus 
configuring a GRK2/Mst2/Nek2 kinase cascade. EGFR 
phosphorylation of tyrosine residues in GRK2 may foster 
its catalytic activity toward Mst2, which could add to the 
disjunction mechanism triggered by PLK1 in prophase to 
make centrosome separation faster and earlier in G2.
Downregulation of GRK2 in G2 might also restrain the 
level of cyclin B1 upregulation at G2/M transition. Cyc-
lin B1 levels are regulated via periodic transcription and 
dynamic shuttling into and out of the nucleus. Both tran-
scription and influx into the nucleus peak in late G2, when 
accumulated cyclin B1 can bind and activate CDK1 for 
mitosis onset. As part of the mechanisms that counteract 
a constitutive nuclear import and premature CDK1 activa-
tion, cyclin B is retained in the cytoplasm by means of its 
association with Patched1 [163]. Interestingly, GRK2 inter-
acts with Patched1 and inhibits cyclin B1–Patched 1 interac-
tion, allowing for cyclin B1 nuclear accumulation and G2/M 
transition, whereas GRK2 knockdown in cells and zebrafish 
results in cell cycle arrest in G2/M stage with accumulation 
of the mitotic marker pH3 pointing to mitosis failure [150].
In contrast to the catalytic function of GRK2 in Mst2 
regulation and centrosome disjunction, regulation of cyclin 
B1-mediated cell proliferation involves a physical interac-
tion of GRK2 with Patched1. Therefore, both scaffold and 
catalytic functions of GRK2 coexist in the control of cell 
cycle during G2/M progression. This complexity would add 
to the multifactorial role of GRK2 in other transitions of the 
cell cycle, which are not equally exhibited in the prolifera-
tion status of tissues and organs throughout the body, and 
may help to understand the marked discrepancies in phe-
notypes in animal models with GRK2 deficiency (global 
vs. tissue-specific, developmental vs. adult-inducible, total 
vs. partial). While partial decrease of GRK2 dosage/activity 
might be beneficial to treat some pathological conditions 
(e.g., cardiovascular conditions or metabolic syndrome, 
[18]), sharp and continued reduction of its activity may 
cause alterations in tissue/organ proliferation. For instance, 
mice engineered to globally express an shGRK2 transgene 
to knockdown the kinase without compromising embryonic 
development, were smaller in size with lower body weight 
in the adulthood [164] and exhibited renal hypotrophy with 
reduced glomerular filtration, reduced number of mature 
glomeruli, and increased hypertension due to overactivation 
of the renin–angiotensin system [165]. While hypertension 
is completely reversed by AT1R blockers, defective glo-
merular filtration is not, suggesting that non-hemodynamic 
functions related to mesangial proliferation and hypertrophy 
are altered in the absence of GRK2.
Emerging roles of the GRK2–HDAC6 signaling axis
The reported functional interaction between GRK2 and 
HDAC6 (histone deacetylase 6) constitutes a very interesting 
and prototypic example of stimulus- and context-dependent 
GRK2 multifunctionality, with potentially relevant implica-
tions in a variety of physiological processes and pathological 
conditions, including epithelial cell motility, viral infection 
or breast cancer progression.
GRK2 and HDAC6 were first identified as signaling part-
ners in the context of cell migration. GRK2 had been shown 
to play a negative modulatory role in chemokine receptor-
mediated immune cell migration, consistent with its canoni-
cal role in agonist-induced GPCR desensitization [166–170]. 
However, the role of GRK2 in cell motility is more com-
plex, and involves the modulation of diverse phases of this 
process in a stimulus- and a cell type-specific manner [20]. 
Strikingly, GRK2 was shown to play a positive role in the 
migration of epithelial cells and fibroblasts in response to 
the stimulation of either the sphingosine-1-phosphate (S1P)/
S1P1R (a GPCR family member) or fibronectin-mediated 
integrin activation [64]. In response to these stimuli, GRK2 
transiently interacts with the ARF GTPase-activating pro-
tein GIT1 (Mammalian G protein-coupled receptor kinase 
InTeractor 1) [171] at the cell leading edge. Interestingly, 
the GRK2/GIT1 interaction was dynamically modulated by 
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the GRK2 phosphorylation status by c-Src or MAPK. Rapid 
migratory stimuli-triggered GRK2 tyrosine phosphorylation 
in epithelial cells favors GRK2/GIT1 interaction, and thus 
localized Rac1/PAK/MEK/ERK activation [64]. In turn, 
GRK2 phosphorylation at S670 by ERK1/2 decreases its 
ability to associate with GIT1, allowing dynamic assembly/
disassembly of these actin cytoskeleton modulatory scaf-
folds [20, 64, 172].
Importantly, such GRK2 S670 phosphorylation event 
taking place in epithelial cells in response to the presence 
of serum, EGF, or other activators of the MAPK pathway, 
not only disrupts the GRK2/GIT1 signalosome but also pro-
motes the functional interaction of GRK2 with the cytosolic 
histone deacetylase type II protein HDAC6. Phosphorylation 
of HDAC6 by GRK2 at residues S1060, 1062, and 1069 
promotes increased deacetylation of alpha-tubulin, a well-
known HDAC6 target [173], consequently allowing GRK2 
to modulate microtubule (MT) dynamics, and thus cell 
motility and spreading [71].
It is important to note that S670 phosphorylation at the 
C terminus of the kinase is relevant for the triggering of the 
GRK2/HDAC6 module not only by favoring GRK2 dissocia-
tion from competing cellular partners such as GPCRs [69] 
or GIT-1 [64], likely by altering electrostatic interactions 
involved in their binding, but also by fostering a competent 
conformation at the GRK2 active site that allows phospho-
rylation of HDAC6 [71]. Since it has been proposed that an 
allosteric interaction occurs between the C-tail PH domain 
and the RH domain of GRK2, it is tempting to suggest that 
alterations initiated by the phosphorylation at S670 would 
be conveyed to the catalytic domain (Fig. 1), affecting its 
conformation and promoting a switch in substrate specificity.
Therefore, GRK2 phosphorylation events are instrumen-
tal to locally and rapidly switch the repertoire of GRK2 sub-
strates and cellular partners (see Fig. 2), thus specifying the 
preferred targets of this multifunctional kinase in a dynamic 
and context-specific way [20, 71]. In the framework of epi-
thelial cell migration, sequential changes in the tyrosine and 
S670 phosphorylation status of GRK2 would allow the coor-
dinated participation of GRK2/GIT1 and GRK2/HDAC6 
signalosomes in several steps of the motility process.
These data suggested that the GRK2/HDAC6 signal-
ing module might be particularly operative and relevant in 
pathological contexts characterized by increased expression 
of these proteins and/or high activation of ERK1/2 transduc-
tion cascades. On the other hand, they raised the question 
of whether GRK2-mediated HDAC6 phosphorylation may 
also affect the activity of the deacetylase toward additional 
cellular targets [174]. Consistent with this notion, recent data 
have emphasized a relevant role for the GRK2/HDAC6 axis 
in breast cancer [12, 19, 111]. Notably, GRK2 protein lev-
els are increased in a variety of breast cancer cell lines, in 
spontaneous mammary tumors developing in MMTV-HER2 
transgenic mice, and in a significant proportion of two inde-
pendent groups of invasive ductal carcinoma patients [111], 
in which luminal subtypes predominate.
Importantly, such GRK2 upregulation in breast cancer 
cells would concur with that of HDAC6, known to be over-
expressed in these tumor contexts [111, 175, 176], as well 
as with increased phosphorylation of GRK2 on S670 [111] 
as a consequence of the hyperactivation of ERK1/2 down-
stream of hyperactivated EGFR, HER2, estrogen receptors, 
or alterations in the Ras pathway often found in both lumi-
nal and basal breast cancer contexts. Such conditions would 
favor the switch of the GRK2/HDAC6 axis.
In fact, this module appears to play a relevant role in 
fostering proliferation and survival of transformed breast 
cells, by mechanisms involving GRK2-mediated HDAC6 
activation and the modulation of the acetylation status of 
a newly identified HDAC6 substrate, the prolyl isomerase 
Pin1, a fundamental cancer driving node also described to 
be present in such pathological conditions [177].
Enhanced GRK2 protein in breast cells strengthens 
EGF or heregulin-triggered mitogenic (ERK1/2) and sur-
vival (AKT) cascades, fosters proliferation, survival and 
anchorage-independent growth of luminal MCF7 or MDA-
MB-231 basal cancer cells, and increases tumor growth 
in vivo in xenograft and orthotopic mouse models [111]. 
On the contrary, silencing GRK2 expression has opposite 
effects in both luminal and basal breast cancer cells [111, 
178]. The molecular mechanisms underlying such positive 
effects of GRK2 on oncogenic hallmarks appear to involve 
the modulation of the HDAC6/Pin1 axis downstream of 
EGFR activation. On the one hand, given that both GRK2 
and HDAC6 can interact with the EGFR [2, 21, 60, 179, 
180], that EGF triggers GRK2 phosphorylation at S670 [2] 
and that HDAC6 potentiates EGF signaling by lessening 
EGFR internalization [179, 180], it is tempting to suggest 
that phosphoS670-GRK2-enhanced HDAC6 deacetylase 
activity would allow sustained EGFR signaling by down-
regulating EGFR internalization [179]. On the other hand, 
EGF stimulation triggers rapid HDAC6 and Pin1 association 
and de-acetylation of Pin1 at K46, a process fostered by 
increased GRK2 expression [111]. In turn, Pin1 deacetyla-
tion augments its stability, its prolyl isomerase activity, and 
the interaction with key downstream oncogenic mediators. 
Acetylation–deacetylation-mediated variations in charge 
at K46 might alter the inter-domain linker folding in Pin1, 
leading to allosteric conformational changes that enhance 
Pin1 ligand affinity and catalytic activity [111]. Consistent 
with a relevant pathological role for GRK2-medited changes 
in Pin1 acetylation status, GRK2 expression and Pin1 levels 
and de-acetylation status correlate in both cell models and 
in samples from breast cancer patients [111].
In summary, the EGFR–GRK2–HDAC6–Pin1 axis 
emerges as a relevant signature and potential therapeutic 
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target in breast cancer. Several key questions remain to be 
addressed. First, does the GRK2/HDAC6 module promote 
changes in the acetylation status and activity of other players 
in breast tumor progression? Do other stimuli also trigger 
this axis? Are there additional cellular substrates for GRK2 
that depend on its prior phosphorylation at S670? These 
results also raise the possibility that this GRK2/HDAC6 
module could also be relevant in other cell types and patho-
logical conditions in which these molecules are known to 
be involved. In this regard, our unpublished observations 
suggested a role for the GRK2/HDAC6/Pin1 axis in certain 
cardiac pathological conditions (Penela et al. in preparation).
Other potentially interesting context is viral infection. 
Histone deacetylase 6 (HDAC6) plays both enzymatic 
and scaffold roles in diverse cellular processes including 
autophagy, pathogen sensing, and cellular cargo move-
ment, related to infection and innate immunity. HDAC6-
mediated deacetylation reduces microtubule stability and 
impairs kinesin and dynein-dependent transport of vari-
ous cargoes, and such movement mechanisms are co-opted 
by pathogens, including viruses and intracellular bacteria 
[181–183]. HDAC6 has also been related to the regulation of 
viral fusion, entry, nuclear trafficking, replication, assembly, 
and egress [182]. Interestingly, GRK2 has been shown to 
support infection of several flaviviruses, such as yellow fever 
virus (YFV), dengue virus (DENV), and Hepatitis C virus 
(HCV) [184], and a recent report using quantitative phos-
phoproteomics in A549 human lung epithelial cells indicates 
that GRK2 is crucially involved in the initial steps of Influ-
enza A virus (IAV) infection [185]. GRK2 pharmacological 
inhibitors or siRNA kinase silencing decreases IAV uncoat-
ing and limits viral replication in primary human airway 
epithelial cultures and in established mice models [185]. Of 
note, GRK2 kinase activity is required for IAV uncoating 
and the role of this kinase requires a cellular target and is 
independent of beta-arrestin functions.
IAV harnesses the host endocytic machinery to enter the 
cell and traffic to reach the replication site in the nucleus. 
Interaction of viral hemagglutinin with plasma membrane 
proteins has been suggested to induce clustering and activa-
tion of receptor tyrosine kinases such as the EGFR, lead-
ing to stimulation of PI3K and ERK1/2 downstream cas-
cades and endocytosis, all processes relevant to engulfing 
of viral particles and for endosomal acidification leading to 
viral fusion [185, 186]. Importantly, IAV infection induced 
EGFR-dependent GRK2 phosphorylation at tyrosine resi-
dues and its translocation to EGFR-containing plasma mem-
brane clusters [185]. Given that HDAC6 is recruited to viral 
fusion sites and suggested to allow efficient un-coating by 
complex mechanisms involving the aggresome machinery 
[187], and considering previous reports showing EGFR/
GRK2/HDAC6 functional interactions [58, 60, 71, 111], it 
is tempting to suggest that this module may underlie GRK2 
pro-viral function. Whether GRK2–HDAC6 axis is con-
trolling these processes, it is a matter of further research. 
However, the relationship might not be straightforward. The 
phosphoproteomic analysis did not detect GRK2 or HDAC6 
serine phosphopeptides, although this could be due to tran-
sient phosphorylation or protein abundance issues. It is also 
possible that, in this context, GRK2 might be alternatively 
activated via tyrosine phosphorylation [58, 60] downstream 
IAV/EGFR stimulation. However, α-tubulin deacetylation 
is not required for viral uncoating [187]. Therefore, further 
investigation should address whether the acetylation status 
of other targets downstream the GRK2/HDAC6 axis and/
or phosphorylation of additional GRK2 substrates upon 
IAV/EGFR-mediated GRK2 tyrosine phosphorylation, and 
translocation are involved in the role of this multifunctional 
kinase in viral infection.
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